Cerevel Therapeutics Holdings Inc is a United States-based company. The Company is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimerâ€™s disease psychosis, epilepsy, panic disorder and Parkinsonâ€™s disease.

Employees

355

Sector

Biotechnology & Medical Research

More about the company

Delayed Nasdaq 06:00:00 01/08/24 am AEST			5-day change	1st Jan Change
44.96 ^USD	+0.74%		-.--%	-

05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Biotechnology Select Industry Index	CI
05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Global BMI Index	CI

Market Cap	8.19B 7.04B 6.63B 6.05B 11.31B 775B 11.35B 78.56B 30.37B 397B 30.76B 30.09B 1,264B	P/E 2022	-13.6x	P/E 2023	-15.9x
Enterprise Value	7.5B 6.45B 6.06B 5.53B 10.35B 709B 10.39B 71.89B 27.79B 363B 28.15B 27.54B 1,156B	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	93.64%	Yield 2022 *	-	Yield 2023	-

05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Biotechnology Select Industry Index	CI
05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Global BMI Index	CI
05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P TMI Index	CI
02/08/24	Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
01/08/24	AbbVie Completes Acquisition of Cerevel Therapeutics	MT
01/08/24	AbbVie Completes Acquisition of Cerevel Therapeutics	MT
01/08/24	Cerevel Therapeutics Holdings, Inc. Announces Board Changes	CI
01/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from NASDAQ Composite Index	CI
01/08/24	AbbVie Inc. completed the acquisition of Cerevel Therapeutics Holdings, Inc. from FMR LLC and others.	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Dynamic Index	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell Midcap Growth Index	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Index	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from Russell 2000 Index	CI

02/08/24	Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
16/02/24	Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	MT
28/12/23	JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating	MT
22/12/23	Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40	MT
08/12/23	TD Cowen Downgrades Cerevel Therapeutics to Market Perform From Outperform, Price Target is $45	MT

Cerevel Therapeutics Holdings, Inc. Stock

Stocks

CERE

US15678U1280

Biotechnology & Medical Research

Valuation : Cerevel Therapeutics Holdings, Inc.

Latest news : Cerevel Therapeutics Holdings, Inc.

Analysts' recommendations : Cerevel Therapeutics Holdings, Inc.

Press Releases : Cerevel Therapeutics Holdings, Inc.

News in other languages : Cerevel Therapeutics Holdings, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Cerevel Therapeutics Holdings, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

05/04/25	Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.	BU
01/04/25	Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)	BU
01/08/24	AbbVie Completes Acquisition of Cerevel Therapeutics	PR
19/04/24	Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease	AQ
18/04/24	Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease	AQ

02/08/24	RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
22/02/24	USA-Les valeurs à suivre à Wall Street (actualisé)
03/02/24	Omzetdaling Abbvie valt mee
13/12/23	Pharma und Gesundheit: weitere Konsolidierung
13/12/23	Farma en gezondheid: consolidatie gaat door

Manager	Title	Age	Since
John Renger CTO	Chief Tech/Sci/R&D Officer	57	01/05/2019
Matthew Calistri IRC	Investor Relations Contact	-	-
Paul Burgess PRN	Corporate Officer/Principal	53	20/06/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/8/24	Ramiro Sánchez	Issuer sale	Chief Medical Officer	1,495,399	0.8208%
1/8/24	Douglas Giordano	Issuer sale	Director	108,985	0.0598%
1/8/24	Marijn Dekkers	Issuer sale	Director	137,525	0.0755%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CEREVEL THERAPEUTICS HOLDINGS, INC.	+0.74%	-.--%	-.--%	+87.10%	8.19B
WUXI APPTEC CO., LTD.	+2.02%	+1.01%	+45.58%	+104.91%	67.82B
ARGENX SE	-0.41%	-2.30%	+33.53%	+78.63%	63.22B
INSMED INCORPORATED	-0.83%	+2.74%	-14.89%	+375.40%	27.58B
BIONTECH SE	-5.10%	-3.22%	-3.89%	-17.87%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	+1.69%	+0.94%	+33.46%	+17.80%	25.38B
GENMAB A/S	+1.12%	+0.84%	+24.50%	-17.84%	19.89B
PHARMAESSENTIA CORPORATION	+6.04%	+0.72%	+239.13%	+407.95%	17.4B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.49%	-1.85%	-6.87%	+546.36%	14.95B
EXELIXIS, INC.	-0.20%	+2.67%	+54.97%	+164.18%	14.62B
Average	+0.43%	+2.25%	+40.55%	+174.66%	28.51B
Weighted average by Cap.	+0.41%	+1.50%	+38.22%	+141.88%

	2022	2023
Net sales	-	-
Net income	-352M -302M -284M -260M -485M -33.24B -487M -3.37B -1.3B -17.02B -1.32B -1.29B -54.23B	-433M -372M -350M -320M -598M -40.94B -600M -4.15B -1.6B -20.96B -1.63B -1.59B -66.77B
Net Debt	-523M -450M -423M -386M -723M -49.48B -725M -5.02B -1.94B -25.34B -1.96B -1.92B -80.72B	-695M -598M -562M -513M -960M -65.77B -963M -6.67B -2.58B -33.68B -2.61B -2.55B -107B

3 years	19.59	44.99
5 years	19.59	46.16
10 years	9	46.16